LT2874630T - Janus kinazės (jak) inhibitorių dozavimas - Google Patents

Janus kinazės (jak) inhibitorių dozavimas

Info

Publication number
LT2874630T
LT2874630T LTEP13742573.2T LT13742573T LT2874630T LT 2874630 T LT2874630 T LT 2874630T LT 13742573 T LT13742573 T LT 13742573T LT 2874630 T LT2874630 T LT 2874630T
Authority
LT
Lithuania
Prior art keywords
jak
inhibitors
dosing regimen
janus kinase
janus
Prior art date
Application number
LTEP13742573.2T
Other languages
English (en)
Inventor
Andrea J. GONZALES
Sallie B. COSGROVE
Phyllis B. MALPAS
Michael Rolf STEGEMANN
Wendy Turner COLLARD
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2874630(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of LT2874630T publication Critical patent/LT2874630T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
LTEP13742573.2T 2012-07-20 2013-07-18 Janus kinazės (jak) inhibitorių dozavimas LT2874630T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
LT2874630T true LT2874630T (lt) 2019-02-11

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13742573.2T LT2874630T (lt) 2012-07-20 2013-07-18 Janus kinazės (jak) inhibitorių dozavimas

Country Status (24)

Country Link
US (1) US9522151B2 (lt)
EP (1) EP2874630B1 (lt)
JP (2) JP6022063B2 (lt)
KR (2) KR20170034949A (lt)
CN (2) CN108354938A (lt)
AU (1) AU2013292547B2 (lt)
BR (1) BR112015000808A2 (lt)
CA (1) CA2878867C (lt)
CY (1) CY1121436T1 (lt)
DK (1) DK2874630T3 (lt)
ES (1) ES2707627T3 (lt)
HK (2) HK1209314A1 (lt)
HR (1) HRP20182088T1 (lt)
HU (1) HUE042771T2 (lt)
IN (1) IN2015DN00370A (lt)
LT (1) LT2874630T (lt)
MX (1) MX360857B (lt)
NZ (1) NZ703152A (lt)
PL (1) PL2874630T3 (lt)
PT (1) PT2874630T (lt)
RS (1) RS58242B1 (lt)
SI (1) SI2874630T1 (lt)
WO (1) WO2014015107A1 (lt)
ZA (1) ZA201500134B (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037192T2 (hu) 2013-02-22 2018-08-28 Pfizer Pirrolo [2,3-D]pirimidin származékok mint a Janus-kinázok (JAK) inhibitorai
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
SG11201802990RA (en) 2015-10-16 2018-05-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR20210120074A (ko) * 2019-01-30 2021-10-06 가르가멜 (주하이) 바이오테크 리미티드 Jak 억제제 및 그 제조 방법
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
ES2467109T3 (es) * 2008-08-20 2014-06-11 Zoetis Llc Compuestos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
HK1209314A1 (en) 2016-04-01
AU2013292547B2 (en) 2017-05-04
JP2017019816A (ja) 2017-01-26
JP6022063B2 (ja) 2016-11-09
AU2013292547A1 (en) 2015-01-22
CA2878867C (en) 2018-01-09
US20150126535A1 (en) 2015-05-07
JP2015522620A (ja) 2015-08-06
CY1121436T1 (el) 2020-05-29
PT2874630T (pt) 2019-01-31
MX2015000871A (es) 2015-05-07
PL2874630T3 (pl) 2019-04-30
BR112015000808A2 (pt) 2017-06-27
HK1252083A1 (zh) 2019-05-17
IN2015DN00370A (lt) 2015-06-12
WO2014015107A1 (en) 2014-01-23
EP2874630B1 (en) 2018-12-05
US9522151B2 (en) 2016-12-20
SI2874630T1 (sl) 2019-04-30
CN104470525A (zh) 2015-03-25
CA2878867A1 (en) 2014-01-23
MX360857B (es) 2018-11-20
KR20170034949A (ko) 2017-03-29
NZ703152A (en) 2016-03-31
EP2874630A1 (en) 2015-05-27
CN108354938A (zh) 2018-08-03
RS58242B1 (sr) 2019-03-29
ES2707627T3 (es) 2019-04-04
HRP20182088T1 (hr) 2019-02-08
HUE042771T2 (hu) 2019-07-29
DK2874630T3 (en) 2019-01-28
KR20150028299A (ko) 2015-03-13
ZA201500134B (en) 2016-08-31

Similar Documents

Publication Publication Date Title
HRP20182088T1 (hr) Režim doziranja za inhibitore janus kinaze (jak)
HK1254429A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1212683A1 (zh) 多個激酶途徑抑制劑
HK1222647A1 (zh) 激酶抑制劑
EP2758051A4 (en) CYANOMETHYLPYRAZOLCARBOXAMIDES AS JANUS KINASEINHIBITORS
HUE048834T2 (hu) Kináz inhibitorok
HK1211574A1 (en) Serine threonine kinase inhibitors
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
PL2634185T3 (pl) Inhibitory kinazy TYK2
IL229028A0 (en) Kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
HK1199873A1 (en) Kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑